NDATOPICALSOLUTION
Approved
Jul 2023
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
9
Data completeness
4/8 — Partial
Drug data last refreshed 33m ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
YCANTH (cantharidin) is a topical solution approved by the FDA in July 2023 for the treatment of viral skin lesions, specifically common warts. It is a naturally derived compound that works through a blister-inducing mechanism to remove affected tissue. The product represents a non-invasive alternative to traditional wart removal methods.
Peak14.4 years to LOE
Product is in peak commercial phase with established market entry; territory and account management roles indicate active field sales expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (9)
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)
Started Jun 2026
300 enrolled
Common WartsCommon Warts (Verruca Vulgaris)Human Papilloma Virus (HPV)+1 more
Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)
Started Mar 2026
600 enrolled
Common Warts (Verruca Vulgaris)Common WartsHuman Papilloma Virus (HPV)+1 more
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)
Started Dec 2025
300 enrolled
Common WartsCommon Warts (Verruca Vulgaris)Human Papilloma Virus (HPV)+1 more
Cantharidin and Occlusion in Verruca Epithelium
Started Mar 2018
56 enrolled
Common WartWarts HandWarts+9 more
Cantharidin Application in Molluscum Patients-1
Started Mar 2018
266 enrolled
Molluscum Contagiosum
Worked on YCANTH at Verrica Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.